| Verapamil Hydrochloride Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Verapamil Hydrochloride 80 mg | tablet | oral | 1.0 each | OTC |
| Verapamil Hydrochloride 120 mg | tablet | oral | 1.0 each | OTC |
| Verapamil Hydrochloride 40 mg | tablet | oral | 1.0 each | OTC |
| Verapamil Hydrochloride 2.5 mg/mL | solution | intravenous | 1.0 milliliter(s) | OTC |
| Verapamil Hydrochloride - | powder | compounding | 100.0 gram(s) | OTC |
Posted by she 4 months ago
I have taken Verapamil for 5 days now for migraine. My blood pressure was in a good low area before, now it it high??? Shou...
Posted by davidonslow 5 months ago
I have been on Securon Verapamil for over 5 years,together with Digoxin and warfarin, prescribed for atrial fibrillation.
Ha...
Posted by cdesertheat about 1 year ago
I was put on Verapamil 120mg after being taken off of Atenolol which I had been on for 5 years. I also took Lisinipril along...
Eisai Announces Vasolan(R) (Ischaemic Heart Disease Treatment ... - Japan Corporate News (press release)
... Ltd. (TSE: 4523) announced today that Vasolan(R) Tablets 40mg (generic name: verapamil hydrochloride) received approval for the additional indications ...
Tue Mar 04 09:26:42 -0500 2008
Eisai Announces Vasolan(R) (Ischaemic Heart Disease Treatment ... - Japan Corporate News (press release)
... Ltd. (TSE: 4523) announced today that Vasolan(R) Tablets 40mg (generic name: verapamil hydrochloride) received approval for the additional indications ...
Tue Mar 04 09:26:42 -0500 2008
Oral Verapamil HCl Approved in Japan for Tachyarrhythmia - DG News
TOKYO -- March 4, 2008 -- Verapamil hydrochloride (Vasolan) 40 mg tablet has been approved for atrial fibrillation/flutter and paroxysmal supraventricular ...
Tue Mar 04 15:38:49 -0500 2008
verapamil hydrochloride - The hydrochloride form of Verapamil, which is a phenylalkylamine calcium channel blocking agent. Verapamil inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)